Docket No. 283

283829US0PCT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Thomas RUECKLE, et al.

SERIAL NO: 10/565,976

GAU:

FILED:

10/303,370

EXAMINER:

FOR:

January 26, 2006

2-IMINO-4-(THIO) OXO-5-POLY CYCLOVINYLAZOLINES FOR USE AS P13 KINASE IHIBITORS

# **INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

#### REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

### RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

### CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

### **DEPOSIT ACCOUNT**

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number <u>15-0030</u>. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

U.S. PCT Application Serial No: 10/565,976

Filed: January 26, 2006 Thomas RUECKLE, et al. Docket No. 283829 US

# STATEMENT OF RELEVANCY

- 1) References AO & AW have been cited in the International Search Report. A copy of these references is being submitted herewith.
- 2) References AP & AAV AAW have been cited in the corresponding Partial European Search Report. A copy of these references is being submitted herewith.
- 3) References AX AAU are discussed in the specification. A copy of these references is being submitted herewith.
- 4) References are additional prior art known to Applicant. A copy of these references is being submitted herewith.

(Modified) PATENT AND TRADEMARK OFFICE 283829US0PCT APPLICANT Thomas RUECKLE, et al. FILING DATE GROUP								
LIST OF REFERENCES CITED BY APPLICANT Thomas RUECKLE, et al.  FILING DATE GROUP								
FILING DATE GROUP								
- January 26, 2006								
U.S. PATENT DOCUMENTS								
EXAMINER DOCUMENT DATE NAME CLASS SUB FILING CLASS IF APPRO								
AA								
AB								
AC								
AD								
AE								
AF								
AG	_							
AH								
Al								
AJ								
AK								
AL								
AM								
AN								
FOREIGN PATENT DOCUMENTS								
DOCUMENT DATE COUNTRY TRANSLATIC YES	NO NO							
AO 0 697 410 02/21/96 EP	NO							
AP 5-2200 01/08/93 JP (with English abstract)	NO							
AQ								
AR	·							
AS								
AT								
AU	<del></del>							
AV								
OTHER REFERENCES (Including Author Title Date Particular Bases at a)								
	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)  ROUE, Nathalie et al., "Synthesis of the marine alkaloid leucettamine B", Tetrahedron, Vol. 55, No. 51, Pages 14729-14738,							
BRUMMOND, Kay M. et al., "Solid-Phase Synthesis of BRL 49653", J. Org. Chem., Vol. 64, Pages 1723-1726, 1								
AX								
AY PROBLEM, et al., "Regulation of Interleukin-2 Gene Enhancer Activity by the T Cell Accessory Molecule CD28", So 251, Pages 313-316, 1991.	FRASER, et al., "Regulation of Interleukin-2 Gene Enhancer Activity by the T Cell Accessory Molecule CD28", Science, Vol. 251, Pages 313-316, 1991.							
FRUMAN, David A. et al., "Phosphoinositide Kinases", Ann. Rev. Biochem, Vol. 67, Pages 481-507, 1998.  AZ  Additional References sheet(								
Examiner Date Considered	Date Considered							
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO.	SERIAL NO.			
(Modified)		290542US2PCT	10/565,976			
		APPLICANT				
LIST OF RE	FERENCES CITED BY APPLICANT	Stefan Martin Benjamin GACHTER				
-		FILING DATE	GROUP			
		January 26, 2006				
-	OTHER REFERENCES	Including Author, Title, Date, Pertinent	Pages, etc.)			
A	GERARD, Craig et al., "Chemokines	and disease", Nature Immunology, Vol. 2,	No. 2, Pages 108-115, 2001.			
A	HIRSCH, Emilio et al., "Resistance to 2021, 2001.	o thromboembolism in PI3Ky-deficient mice <sup>1</sup> " FASEB, Vol.15, Part 11, Pages 2019-				
A	HIRSCH, Emilio et al., "Central role for G protein-coupled phosphoinositide 3-Kinase y in inflammation", Science, Vol. 287, Part 5455, Pages 1049-1053, 2000.					
A	LOPEZ-ILASACA, Marco et al., "Phosphoinositide 3-Kinase y is a mediator of Gβγ-dependent jun kinase activation", The Journal of Biological Chemistry, Vol. 273, No. 5, Pages 2505-2508, 1998.					
A	dimethylbenzofuran derivatives as ga Journal of Med. Chem., Vol. 41, No.	JANUSZ, John M. et al., "New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3, 3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations at the 5 position", Journal of Med. Chem., Vol. 41, No. 18, Pages 3515-3529, 1998.				
A	KATSO, Roy et al., "Cellular function of phosphoinositide 3-Kinases: Implications for development, immunity, homeostasis, and Cancer, "Annu. Rev. Cell Dev. Biol., Vol. 17, Pages 615-675, 2001.					
A	LAFFARGUE, Muriel et al., "Phosphoinositide 3-Kinase γ is an essential amplifier of mast cell function", Immunity, Vol. 16, No. 3, Pages 441-451, 2002.					
A	LAWLOR, Margaret A. et al., "PKB/Akt: a key mediator of cell proliferation, survival and insulin responses", Journal of Cell Science, Vol. 114, No. 16, Pages 2903-2910, 2001.					
A	LESLIE, Nick R. et al., "Phosphoinositide-regulated Kinases and Phosphoinositide phosphatases", Chem. Rev., Vol. 101, No. 8, Pages 2365-2380, 2001.					
A	PAGES, Francoise et al., "Binding of phosphatidyl-inositol-3-OH kinase to CD28 is required for T-cell signalling", Nature, Vol 369, Pages 327-329, 1994.					
A	PANAYOTOU, George et al., "Phosphatidyl-inositol 3-kinase: a key enzyme in diverse signalling processes", Trends in Cell Biology, Vol. 2, Pages 358-360, 1992.					
A	PARKER, Peter J. et al., "PI 3-kinase puts GTP on the rac", Current Biology, Vol. 5, No. 6, 1995.					
AA	RUDD, Christopher E. et al., "Upstream-downstream: CD28 cosignaling pathways and T cell function", Immunity, Vol. 4, Pages 527-534, 1996.					
AA	STEIN, Robert C. et al., "PI3-kinase inhibition: a target for drug development?", Molecular Medicine Today, Vol. 6, No. 9, Pages 347-357, 2000.					
AA	STEPHENS, Len, et al., "Roles of PI3Ks in leukocyte chemotaxis and phagocytosis", Current Opinion Cell. Biol., Vol. 14, No. 2, Pages 203-213, 2002.					
AA	THELEN, Marcus et al., "Wortmanning binding protein-coupled receptor sign	al., "Wortmannin binds specifically to 1-phosphatidylinositol 3-kinase while inhibiting guanine nucleotide- ed receptor signaling in neutrophil leukocytes", Proc. Natl. Acad. Sci, Vol. 91, Pages 4960-4964, 1994.				
AA	TOKER A. et al., "Phosphoinositides 761-779, 2002.	A. et al., "Phosphoinositides and signal transduction", Cellular and Molecular Life Sciences, Vol. 59, No. 5, Pages 2002.				
Examiner		1	Date Considered			
*Examiner: Initial	if reference is considered, whether or not	citation is in conformance with MPEP 609	; Draw line through citation if not in			

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO.	SERIAL NO.		
			283829US0PCT	10/565,976		
LIST OF REFERENCES CITED BY APPLICANT			APPLICANT			
		RENCES CITED BY APPLICANT	Thomas RUECKLE, et al.			
			FILING DATE	GROUP		
			January 26, 2006			
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)						
	AAR	VANHAESEBROECK, B. et al., "Signaling by distinct classes of phosphoinositide 3-kinases", Experimental Cell Research, Vol. 253, Part 1, Pages 239-254, 1999.				
	AAS	VANHAESEBROECK, Bart, et al., "Phosphoinositide 3-kinases: a conserved family of signal transducers", Trends Biochem. Sci., Vol. 22, No. 7, Pages 267-272, 1997.				
	AAT	WYMANN, Matthias P. et al., "Lipids on the move: phosphoinositide 3-kinases in leukocyte function", Immunology Today, Vol. 21, No. 6, Pages 260-264.				
	AAU	YAO, Ryoji et al., "Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor", Science, Vol. 267, Pages 2003-2006, 1995.				
	AAV	"Chemical Block Stock Library", XP002263803, 2003				
	AAW	"ChemDiv Inc. Product Library", XP002263804, 2003.				
Examiner				Date Considered		
			t citation is in conformance with MPEP 609 with next communication to applicant.	); Draw line through citation if not in		